drugset
drugset / Trial / NCT01472016

Study of ABT-700 in Subjects With Advanced Solid Tumors

NCT01472016 ↗

Phase 1 Completed 74 enrolled AbbVie
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-700 in subjects with advanced solid tumors that may have MET amplification or c-Met overexpression. ABT-700, previously known as h224G11 in publications, is an anti-c-Met antibody. The early clinical development plan for ABT-700 is based on the activity demonstrated in preclinical models. Up to 124 subjects will be enrolled.

Timeline

Start
2011-10-06
Primary completion
2017-04-27
Completion
2017-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject TELISOTUZUMAB Monoclonal antibody — Intravenous
Background Cetuximab Monoclonal antibody — Intravenous
Background Docetaxel Small molecule — Intravenous
Background Erlotinib Small molecule — Oral
Background Irinotecan Small molecule — Intravenous
Background Leucovorin Small molecule — Intravenous
Background fluorouracil Small molecule — Intravenous

Indications

No indication recorded.